Market capitalization | CHF5.18b |
Enterprise Value | CHF5.45b |
P/E (TTM) P/E ratio | 69.68 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8.84 |
P/S ratio (TTM) P/S ratio | 8.39 |
P/B ratio (TTM) P/B ratio | 8.33 |
Dividend yield | 0.53% |
Last dividend (FY24) | CHF2.00 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
7 Analysts have issued a Ypsomed forecast:
7 Analysts have issued a Ypsomed forecast:
Sep '24 |
+/-
%
|
||
Revenue | 617 617 |
21%
21%
|
|
Gross Profit | 219 219 |
34%
34%
|
|
EBITDA | 179 179 |
33%
33%
|
EBIT (Operating Income) EBIT | 103 103 |
78%
78%
|
Net Profit | 74 74 |
3%
3%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. Its products include DiaExpert, BGMS, OmniPod, YpsoPump & Orbit, Pen needles, Injection systems, and Contract manufacturing. The company operates through the following business segments: Ypsomed Diabetes Care, and Ypsomed Delivery Systems. The Ypsomed Diabetes Care segment owns, manufactures and trade products are marketed under the brand mylife Diabetes care directly to hospitals, physicians, pharmacies and patients via Ypsomed's subsidiaries and distributors. The Ypsomed Delivery Systems segment concerns B2B business and is directly managed by the company. Ypsomed Holding was founded by Wilhelm Michel on December 29, 2003 and is headquartered in Burgdorf, Switzerland.
Head office | Switzerland |
CEO | Simon Michel |
Employees | 2,296 |
Founded | 2003 |
Website | www.ypsomed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.